These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 24629890)

  • 1. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients.
    Vij R; Mazumder A; Klinger M; O'Dea D; Paasch J; Martin T; Weng L; Park J; Fiala M; Faham M; Wolf J
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):131-139.e1. PubMed ID: 24629890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of tumor specific immunoglobulin gene rearrangement in peripheral blood B-cells of multiple myeloma patients by a PCR-SSCP method.
    Wu S; Wang L; Wang Y; Zhu P; Xie G
    Chin Med J (Engl); 1997 Sep; 110(9):682-5. PubMed ID: 9642324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts.
    Vescio RA; Han EJ; Schiller GJ; Lee JC; Wu CH; Cao J; Shin J; Kim A; Lichtenstein AK; Berenson JR
    Bone Marrow Transplant; 1996 Jul; 18(1):103-10. PubMed ID: 8832002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma.
    Puig N; Sarasquete ME; Alcoceba M; Balanzategui A; Chillón MC; Sebastián E; Marín LA; Díaz MG; San Miguel JF; Sanz RG
    Ann Hematol; 2013 Jan; 92(1):97-100. PubMed ID: 22956183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma.
    Rustad EH; Hultcrantz M; Yellapantula VD; Akhlaghi T; Ho C; Arcila ME; Roshal M; Patel A; Chen D; Devlin SM; Jacobsen A; Huang Y; Miller JE; Papaemmanuil E; Landgren O
    PLoS One; 2019; 14(3):e0211600. PubMed ID: 30901326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma.
    Fenk R; Ak M; Kobbe G; Steidl U; Arnold C; Korthals M; Hünerlitürkoglu A; Rohr UP; Kliszewski S; Bernhardt A; Haas R; Kronenwett R
    Haematologica; 2004 May; 89(5):557-66. PubMed ID: 15136219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma.
    Korthals M; Sehnke N; Kronenwett R; Schroeder T; Strapatsas T; Kobbe G; Haas R; Fenk R
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1109-15. PubMed ID: 23644045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of cells with clone-specific immunoglobulin gene rearrangements in the peripheral blood of myeloma patients using immunoglobulin gene fingerprinting.
    Bird JM; Wilmore HP; Samson D
    Eur J Haematol; 1996 Apr; 56(4):259-61. PubMed ID: 8641398
    [No Abstract]   [Full Text] [Related]  

  • 9. ELDA qASO-PCR for High Sensitivity Detection of Tumor Cells in Bone Marrow and Peripheral Blood.
    Huhn S
    Methods Mol Biol; 2018; 1792():1-14. PubMed ID: 29797248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of ancillary studies in the detection of residual disease in plasma cell myeloma in bone marrow.
    Zhao X; Huang Q; Slovak M; Weiss L
    Am J Clin Pathol; 2006 Jun; 125(6):895-904. PubMed ID: 16690489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of minimal residual disease in patients with multiple myeloma using clonotype-specific PCR primers designed from DNA extracted from archival bone marrow slides.
    Takamatsu H; Ogawa Y; Kobayashi N; Obata K; Narisawa T; Nakayama K; Munemoto S; Aoki G; Ohata K; Kumano Y; Ozaki J; Murata R; Kondo Y; Terasaki Y; Kurokawa T; Miyamoto T; Shimizu N; Fukushima T; Yoshida A; Ueda T; Yoshida T; Nakao S
    Exp Hematol; 2013 Oct; 41(10):894-902. PubMed ID: 23727584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma.
    Rustad EH; Misund K; Bernard E; Coward E; Yellapantula VD; Hultcrantz M; Ho C; Kazandjian D; Korde N; Mailankody S; Keats JJ; Akhlaghi T; Viny AD; Mayman DJ; Carroll K; Patel M; Famulare CA; Op Bruinink DH; Hutt K; Jacobsen A; Huang Y; Miller JE; Maura F; Papaemmanuil E; Waage A; Arcila ME; Landgren O
    Am J Hematol; 2019 Dec; 94(12):1364-1373. PubMed ID: 31571261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitation of minimal residual disease in multiple myeloma using an allele-specific real-time PCR assay.
    Rasmussen T; Poulsen TS; Honoré L; Johnsen HE
    Exp Hematol; 2000 Sep; 28(9):1039-45. PubMed ID: 11008016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enrichment of circulating myeloma cells by immunomagnetic beads combined with flow cytometry for monitoring minimal residual disease and relapse in patients with multiple myeloma.
    Wang N; Tesfaluul N; Li J; Gao X; Liu S; Yue B
    Ann Hematol; 2019 Dec; 98(12):2769-2780. PubMed ID: 31748925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoglobulin gene rearrangement in plasma cell dyscrasias: detection of small clonal cell populations in peripheral blood and bone marrow.
    Fend F; Weyrer K; Drach J; Schwaiger A; Umlauft F; Grünewald K
    Leuk Lymphoma; 1993 Jun; 10(3):223-9. PubMed ID: 8220121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.
    van der Velden VH; Jacobs DC; Wijkhuijs AJ; Comans-Bitter WM; Willemse MJ; Hählen K; Kamps WA; van Wering ER; van Dongen JJ
    Leukemia; 2002 Aug; 16(8):1432-6. PubMed ID: 12145681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
    Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
    BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorescent polymerase chain reaction and capillary electrophoresis for IgH rearrangement and minimal residual disease evaluation in multiple myeloma.
    Novella E; Giaretta I; Elice F; Madeo D; Piccin A; Castaman G; Rodeghiero F
    Haematologica; 2002 Nov; 87(11):1157-64. PubMed ID: 12414345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma.
    Yao Q; Bai Y; Orfao A; Kumar S; Chim CS
    J Mol Diagn; 2020 May; 22(5):679-684. PubMed ID: 32151713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple myeloma: disease response assessment.
    Zamagni E; Tacchetti P; Terragna C; Cavo M
    Expert Rev Hematol; 2016 Sep; 9(9):831-7. PubMed ID: 27409577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.